Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

被引：0
|
作者：
Shaohua Zhang
Lei Li
Tao Wang
Li Bian
Haixu Hu
Chunhong Xu
Bing Liu
Yi Liu
Massimo Cristofanilli
Zefei Jiang
机构：
[1] Affiliated Hospital of Academy of Military Medical Sciences,Department of Breast Cancer
[2] Affiliated Hospital of Academy of Military Medical Sciences,Translational Medicine Center, Laboratory of Oncology
[3] Jefferson University Hospital,Department of Medical Oncology
来源：
BMC Cancer | / 16卷
关键词：
Circulating Tumor Cells (CTCs); Human Epidermal Growth Factor Receptor 2 (HER2); Metastatic Breast Cancer (MBC); Anti-HER2 therapy; Real-time HER2 status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
    Zhang, Shaohua
    Li, Lei
    Wang, Tao
    Bian, Li
    Hu, Haixu
    Xu, Chunhong
    Liu, Bing
    Liu, Yi
    Cristofanilli, Massimo
    Jiang, Zefei
    BMC CANCER, 2016, 16
  • [2] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [3] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [4] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [5] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [6] Her2 expression in matched metastatic tumor and circulating tumor cells (ctcs) in breast cancer: Implications for profiling and monitoring of her2 status to help guide anti-her2 therapy
    Stearns, Vered
    Lehman, Jennifer
    Mitchell, Christine
    Blouw, Barbara
    Huynh, Lan
    Singh, Veena
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Eichler, C.
    Quade, A. B.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S40 - S40
  • [8] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Susanna Nguy
    S. Peter Wu
    Cheongeun Oh
    Naamit K. Gerber
    Breast Cancer Research and Treatment, 2021, 187 : 815 - 830
  • [9] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Nguy, Susanna
    Wu, S. Peter
    Oh, Cheongeun
    Gerber, Naamit K.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 815 - 830
  • [10] Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
    Atallah, N. M.
    Alsaleem, M.
    Toss, M. S.
    Mongan, N. P.
    Rakha, E.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1692 - 1705
12345